Featured Research

from universities, journals, and other organizations

Experimental chikungunya vaccine induces robust antibody response

Date:
August 14, 2014
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult volunteers who participated in a recent early-stage clinical trial. The most distinctive symptom of chikungunya infection is severe joint pain accompanied by headache and fever. There are currently no vaccines or specific drug treatments for chikungunya.

A female Aedes aegypti mosquito, one of the two species that spreads chikungunya virus, is shown feeding.
Credit: CDC

An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult volunteers who participated in a recent early-stage clinical trial conducted by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results are reported in the current issue of The Lancet.

Related Articles


The most distinctive symptom of chikungunya infection is severe joint pain accompanied by headache and fever. There are currently no vaccines or specific drug treatments for chikungunya. First identified in East Africa in the early 1950s, chikungunya virus caused sporadic illness in Africa and large urban outbreaks in Thailand and India in the 1960s and 1970s. It first appeared in the Western Hemisphere in late 2013.

As of August 8, more than 570,000 confirmed or suspected cases had been reported throughout the Americas. In the continental United States, 484 cases have been reported as of August 5, and the first two locally acquired infections were detected in Florida in mid-July.

"The two species of mosquito that spread chikungunya virus are found in parts of the continental United States, so it may just be a matter of time before this illness gains a foothold here," said NIAID Director Anthony S. Fauci, M.D. "Therefore, it is prudent to begin addressing this emerging public health threat with the development of vaccines, such as this one, which was designed and tested by scientists from the NIAID Vaccine Research Center."

In 2010, Vaccine Research Center (VRC) scientists and colleagues tested this candidate chikungunya vaccine in non-human primates. All of the immunized animals were protected from infection when later exposed to chikungunya virus.

In the newly reported trial, 23 healthy volunteers received three injections (two other volunteers received two injections) of vaccine at one of three different dosages (10, 20 or 40 micrograms) over a 20-week span. Antibody production was measured at multiple time points following each injection. Investigators detected chikungunya neutralizing antibodies in all volunteers following the second injection, with a significant boost of neutralizing antibodies seen following the third injection. Vaccine-induced antibodies persisted in all volunteers, even those who received the lowest dosage, for at least 11 months after the final vaccination, suggesting that the vaccine could provide durable protection against disease.

"The candidate vaccine prompted a robust immunological response in recipients and was very well tolerated," noted VRC scientist Julie E. Ledgerwood, D.O., principal investigator of the trial. "Notably, the levels of neutralizing antibody produced in response to the experimental vaccine were comparable to those seen in two patients who had recovered from a chikungunya virus infection acquired elsewhere. This observation gives us additional confidence that this vaccine would provide as much protection as natural infection."

Whereas traditional vaccines are typically made from either killed viruses or from weakened live viruses, the experimental vaccine used in the trial is a different type: a virus-like particle (VLP) vaccine. VLP vaccines contain the outer shell proteins of a virus without any of the material the virus needs to replicate inside cells. VLP vaccines often prompt an immune reaction similar to that of natural, whole virus and have a number of potential advantages over traditional vaccines, said Dr. Ledgerwood. Notably, because no live viruses are used in their manufacture, VLP vaccines do not need to be produced under high-level biocontainment conditions.

This candidate vaccine was delivered without an adjuvant -- a substance added to vaccines to improve the immune response -- but still prompted a good response, said Dr. Ledgerwood. If the candidate were to be formulated with an adjuvant, she added, it might be possible to achieve similar immune responses at lower vaccine dosages.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Journal References:

  1. Lee-Jah Chang, Kimberly A Dowd, Floreliz H Mendoza, Jamie G Saunders, Sandra Sitar, Sarah H Plummer, Galina Yamshchikov, Uzma N Sarwar, Zonghui Hu, Mary E Enama, Robert T Bailer, Richard A Koup, Richard M Schwartz, Wataru Akahata, Gary J Nabel, John R Mascola, Theodore C Pierson, Barney S Graham, Julie E Ledgerwood. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. The Lancet, 2014; DOI: 10.1016/S0140-6736(14)61185-5
  2. Wataru Akahata, Zhi-Yong Yang, Hanne Andersen, Siyang Sun, Heather A Holdaway, Wing-Pui Kong, Mark G Lewis, Stephen Higgs, Michael G Rossmann, Srinivas Rao, Gary J Nabel. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nature Medicine, 2010; 16 (3): 334 DOI: 10.1038/nm.2105

Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "Experimental chikungunya vaccine induces robust antibody response." ScienceDaily. ScienceDaily, 14 August 2014. <www.sciencedaily.com/releases/2014/08/140814192112.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2014, August 14). Experimental chikungunya vaccine induces robust antibody response. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2014/08/140814192112.htm
NIH/National Institute of Allergy and Infectious Diseases. "Experimental chikungunya vaccine induces robust antibody response." ScienceDaily. www.sciencedaily.com/releases/2014/08/140814192112.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins